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Abstract 
Context: Application of ultrasound (US) to evaluate attainment and morphology of glandular tissue 
provides a new rationale for evaluating onset and progression of female puberty, but currently no 
hormone references complement this method. Furthermore, previous studies have not explored the 
predictive value of endocrine profiling to determine female puberty onset.
Objective: To integrate US breast staging with hypothalamic-pituitary-gonadal hormone references and 
test the predictive value of an endocrine profile to determine thelarche.
Design Setting and Participants: Cross-sectional sample of 601 healthy Norwegian girls, ages 6 to 
16 years.
Main Outcome Measures: Clinical and ultrasound breast evaluations were performed for all included 
girls. Blood samples were analyzed by immunoassay and ultrasensitive liquid chromatography–tandem 
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Results: References for E2, E1, luteinizing hormone, follicle-stimulating hormone, and sex hormone–
binding globulin were constructed in relation to chronological age, Tanner stages, and US breast stages. 
An endocrine profile index score derived from principal component analysis of these analytes was a 
better marker of puberty onset than age or any individual hormone, with receiver-operating characteristic 
area under the curve 0.91 (P < 0.001). Ultrasound detection of nonpalpable glandular tissue in 14 out of 
264 (5.3%) girls with clinically prepubertal presentation was associated with significantly higher median 
serum levels of E2 (12.5 vs 4.9 pmol/L; P < 0.05) and a distinct endocrine profile (arbitrary units; P < 0.001).
Conclusions: We provide the first hormone references for use with US breast staging and demonstrate 
the application of endocrine profiling to improve detection of female puberty onset.
Keywords: female puberty, estrogen, pediatric endocrinology, references; hormones; principal component analysis
A comprehensive metastudy recently established a statis-
tically significant and still ongoing trend of earlier breast 
development (thelarche, ie, puberty onset) in girls, corres-
ponding to almost 3  months per decade since 1977 (1). 
This finding underlines the need to compile updated ref-
erences for puberty development milestones and pertinent 
hormones used in the diagnosis and management of altered 
puberty onset in the current pediatric population.
Hypothalamic activation initiates female puberty by 
enhanced release of pituitary gonadotropins, mainly lu-
teinizing hormone (LH) and follicle-stimulating hormone 
(FSH) to stimulate gonadal maturation (2). Abnormal cir-
culating levels of FSH and LH in conjunction with gonadal 
hormones can support the diagnosis of pituitary malfunc-
tion, hypogonadism and various disorders of sexual devel-
opment associated with altered puberty onset (3-5). The 
main female sex steroids estrone (E1) and estradiol (E2) are 
involved in development and maintenance of the female 
phenotype and gonadal function. In particular, E2 is an in-
tegral biomarker for assessing female pubertal timing, men-
strual status, and fertility.
Female puberty onset is traditionally defined by breast 
formation, specifically, attainment of palpable glandular 
breast tissue and areolar enlargement, corresponding to 
Tanner stage B2 (6). In contrast, ultrasound (US) leverages 
short-wavelength echogenicity of different tissues to render 
visual representations of internal anatomic structures and 
morphology. Evaluation of breast glandular tissue by US is 
a new approach for assessing female puberty, but its clin-
ical utility remains unexplored and compatible hormone 
references have been lacking. Notably, formation of glan-
dular tissue in early thelarche may be detectable by US 
but not palpable by hand (7). In the pediatric subspecialist 
setting, US breast staging may improve clinical investiga-
tions of altered puberty timing since this method allows for 
storage and objective retrospective assessments of digital 
images during longitudinal patient follow-up. Moreover, 
the procedure is harmless (8, 9); perceived by the patient 
as less invasive than palpation (our unpublished observa-
tions); and provides better definition of breast maturation 
than Tanner stages (10), while being able to differentiate 
between glandular and adipose tissue in overweight girls 
where excess fat accretion may confound traditional breast 
staging by palpation and visual inspection (11, 12). Age ref-
erences for both breast staging by clinical Tanner and US 
breast examinations are provided (Fig. 1) in line with our 
previously published population study (7).
In medicine and biology, principal component analysis 
(PCA) is a statistical approach to stratify patients or iden-
tify phenotype clusters by capturing the variance from sev-
eral variables, or dimensions (13). Previous applications 
of PCA in pediatric research include composite risk index 
scoring for metabolic syndrome (14) and identification of 
allergy phenotypes (15). Endocrine profiling by PCA was 
previously demonstrated to identify distinct subtypes of 
Cushing syndrome (16), improve the predictive value of 
newborn screening for congenital adrenal hyperplasia (17), 
and extract endocrine phenotypes with implications for 
puberty timing in a longitudinal study of female puberty 
(18). However, the utility of a reference endocrine profile 
as diagnostic marker of puberty onset remains unexplored.
From the female pediatric population sample in the 
cross-sectional Bergen Growth Study 2 (BGS2) in Norway, 
we aimed to establish hormone references in relation to 
both traditional Tanner and US breast stages. We lever-
aged a newly established in-house liquid chromatography–
tandem mass spectrometry (LC-MS/MS) method to quantify 
estrogens in the subpicomolar range (19) in order to investi-
gate whether US stratification of clinically prepubertal girls 
would reveal biochemically distinct phenotypes. Lastly, we 
explored the predictive value of hormone biomarkers and 
an endocrine profile to determine female puberty onset.
Materials and Methods
Cohort description
Clinical examinations and data collection for the BGS2 
cross-sectional cohort was conducted in 2016. Children 
in the age interval from 6 to 16 years from 6 schools were 
voluntarily recruited with parental consent to be exam-
ined regarding puberty status. This cohort was described 
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in the cohort (participation rate 49.5%), of whom 651 
donated blood samples. The following participants were 
excluded: 27 due to chronic disease; 12 due to use of oral 
contraceptives, and 11 due to insufficient blood sample 
volume.
Clinical and ultrasound evaluation of puberty
Breast maturation was evaluated both clinically (Tanner B) 
and with US. US images were analyzed after study com-
pletion to prevent observer bias. Clinical evaluation was 
performed in accordance with the schematics proposed by 
Marshall and Tanner (6) and included breast palpation. An 
experienced radiologist established the US staging protocol 
in line with a previous study (20). Description of the mor-
phological distinctions providing the basis for US breast 
staging was provided previously (21). A trained nurse per-
formed all clinical and US evaluations, and the most mature 
breast was examined. Briefly, stage US B0 was characterized 
as a small hypoechoic area in the retro-areolar area. Unique 
to stage US B1 was the presence of hyperechoic tissue with 
a triangular shape. In stage US B2, corresponding to clin-
ical thelarche, the internal breast was characterized by a 
small hypoechoic center (linear, round, or star-shaped) with 
surrounding glandular hyperechoic tissue. The presence of 
a hypoechoic center was a prerequisite for stages US B3 
and US B4, and while the appearance in US B3 was spider-
shaped, the center was defined as increasingly roundish in 
US B4. The mature stage US B5 presented as a heteroge-
neous mass devoid of the hypoechoic center. As described 
previously (21), the intra-observer agreement of US B sta-
ging was “very good” (Cohen’s kappa 0.84; 95% CI, 0.78-
0.91). Presence of pubic hair was defined as a score of 2 or 
higher according to the Tanner PH scale (22).
Blood sample analyses
Samples were collected from venous blood between 8:20 am 
and 2:10 pm. Average time of blood draw was 10:57 am 
and cumulative proportion of samples collected according 
to time of day starting from 08:20 is provided: 09:00 am 
(9%); 10:00 am (30%); 11:00 am (53%); 12:00 pm (69%); 
1:00 pm (88%); 2:00 pm (99%); 2:10 pm (100%). Serum 
was stored at −80  °C prior to analysis at the Hormone 
Laboratory, Department Of Medical Biochemistry and 
Pharmacology, Haukeland University Hospital Hormone 
Laboratory, where personnel were blinded for participant 
age and pubertal status. The laboratory and its analytical 
practice are accredited in accordance with NS-EN ISO 
15189:2012. The following coefficients of variation (CV) 
refer to the inter-assay variation. Siemens IMMULITE 2000 
XPi was used to analyze basal levels of LH (CV 7% at 10 
IU/L), FSH (CV 5% at 17 IU/L) and sex hormone–binding 
globulin (SHBG; CV 6% at 6.74 µg/mL). E2 and E1 were 
analyzed by an ultrasensitive LC-MS/MS method as re-
cently described (23). Briefly, samples were subjected to 
liquid-liquid extraction before analysis and quantification 
by LC-MS/MS. Lower limit of detection (LOD) was 0.28 
pmol/L for E2 and 0.15 pmol/L for E1. Lower limit of quan-
tification (LOQ) was 0.58 pmol/L for E2 (CV 9.1% in the 
range 1.7-153.3 pmol/L) and 0.25 pmol/L for E1 (CV 7.8%; 
range 1.7-143.1 pmol/L). To convert estradiol (E2) to pg/mL, 
divide by 3.671. To convert estrone (E1) to pg/mL, divide by 
3.698. To convert SHBG to µg/mL, divide by 8.896.
Hormone reference intervals
Nonparametric reference intervals were established in ac-
cordance Clinical & Laboratory Standards Institute (CLSI) 
EP28-A3c guidelines (24) and the Canadian Laboratory 
Figure 1. Age reference curves for female puberty. Probit models for age of occurrence for indicated breast stages determined clinically (Tanner B; 
dashed lines) and by ultrasound (US B; solid lines). The US B1 stage was defined by prepubertal breast morphology, but it was radiologically distinct 
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Initiative on Pediatric Reference Intervals (CALIPER) 
framework (25). Briefly, the central 95% range was de-
fined by the lower 2.5th and upper 97.5th percentile 
limits. Reference intervals were established from breast 
stage partitions by resampling to 500 bootstrapped data 
points using the Analyse-it (Analyse-it, Leeds, UK) ex-
tension in Microsoft Excel (Microsoft, Redmond, WA, 
USA). The Harris-Boyd standard deviate test (26-28) 
was applied to log-transformed data with approximate 
Gaussian distributions to determine statistically significant 
differences between pairwise, successive breast stage par-
titions. Justified partitioning criteria were met if the nu-
meric Harris-Boyd z-score exceeded that of the critical z* 
sample power test, as mathematically outlined previously 
(26-29). Continuous hormone reference intervals in rela-
tion to chronological age were generated using the CLSI-
compliant referenceIntervals package in R (R Development 
Core Team, Vienna, Austria), based on a moving window 
of 120 observations as described previously (29).
Endocrine profiling
Data dimensionality reduction by PCA was applied to 
generate a composite endocrine profile score for serum 
level constellations of hormones E1, E2, LH, FSH, and 
SHBG. PCA was applied to hormone data from 403 
premenarcheal girls (age interval, 6.2-15.7  years). 
Participants with missing data for one or more hormones 
were discarded. Postmenarcheal girls were excluded from 
PCA in order to omit menstrual cycle hormone fluctu-
ations. The first principal component 1 (PC1) com-
prised the following loadings: E1 (0.497), E2 (0.494), LH 
(0.475), FSH (0.469), and SHBG (−0.252). This PC1 ex-
hibited an Eigenvalue of 3.6 (ie, its standard deviation of 
1.9 squared) and accounted for 70.0% of the hormone 
dataset variance. Secondary PCs returned Eigenvalues 
below 1.0 and were accordingly discarded. Participant 
PC1 scores were thus used to assign individual endocrine 
profiles in context of the total dataset variance. The PCA 
was computed in R with code operations provided as 
supplemental data (30).
Ethical considerations
The BGS2 was approved by the Norwegian Regional Ethics 
Committee, case references 2015/128/REK and 2015/235/
REK. The study design and conduct conformed to good 
clinical practice and the ethical decrees of the Helsinki 
Declaration. Children younger than 16  years were only 
examined with written and informed parental consent 
and child assent, both of which were instantly revocable. 
Participants were rewarded with a cinema voucher. Breast 
palpation or US performed in the study did not detect any 
pathology.
Statistical analyses
Transition to pubertal breast stage was estimated from age 
using probit regression for a generalized linear model in R, 
as described previously (7). Receiver-operating characteris-
tics (ROC) curves were generated using R and the optimal 
ROC cutoff value (Youden index) was computed using 
with the pROC package, corresponding to the point of the 
ROC curve where the sum of sensitivity and specificity for 
distinguishing 2 groups is highest (31). Statistical signifi-
cance was defined as: * P < 0.05, **P < 0.01, ***P < 0.001 
(2-tailed Mann-Whitney U test) and a z > z* (Harris-Boyd 
test).
Results
Hormone references in relation to 
chronological age
Serum levels of E2, E1, LH, FSH, SHBG, and LH/FSH ratio 
were plotted against age and reference centiles defining 
the 95% normal range and median were computed from 
a moving window of 120 observations (Fig.  2). Table 
format hormone references interpolated from these 
models are provided in SI units in Supplemental Table 
1 (32) and conventional units in Supplemental Table 2 
(33).
Hormones reference intervals by puberty stages
Reference intervals according to breast evaluations by clin-
ical examination (Tanner B stages) and US (US B stages) 
were established by bootstrapping breast stage partitions 
to 500 observations (Table 1). The equivalent table with 
analytes annotated in conventional units is provided as 
Supplemental Table 3 (34). Justified partitioning of in-
cremental breast stage reference intervals was verified 
using the pairwise Harris-Boyd standard deviate test (Z). 
Where indicated not significant (n.s.), the reference interval 
overlap of the current and the previous partition was too 
extensive to warrant partitioning despite the dichotomized 
segregation by breast stages. By the same logic, standard 
deviate testing of corresponding Tanner B and US B stage 
reference intervals (ie, Tanner B2 vs US B2, with matching 
increments) showed agreement between the 2 methods 
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distinctions for any of the 5 hormones. Median ages (95% 
CI) for the Tanner B stages were: B1, 8.7 (6.6-11.6); B2, 
10.6 (8.5-13.8); B3, 11.9 (10.2-15.1); B4, 14.0 (11.6-
16.0), and B5, 14.6 (11.7-16.0) years. Median ages for the 
US B stages were: US B0, 8.2 (6.5-11.4); US B1, 8.9 (6.8-
11.9); US B2, 10.6 (8.3-13.8); US B3, 12.0 (9.6-15.8); US 
B4, 13.8 (11.2-16.0), and US B5, 14.4 (12.1-16.0) years.
Endocrine profile detects thelarche
Next, we evaluated the predictive value of age, endocrine 
profile, and individual analytes, respectively, in determining 
the transition to puberty onset defined by attainment of 
breast stage Tanner B2+ or US B2+ (Table  2). For these 
analyses, we selected the age interval 8.0 to 12.0 years that 
defined both the earliest and latest occurrence of Tanner B2 
in the dataset. Statistically significant differences were ob-
served for all variables between prepubertal and pubertal 
groups (P < 0.001 for all, Mann-Whitney U). Notably, 
the endocrine profile index (ie, participant PC1 scores) 
returned the highest area under the ROC curve and best 
negative predictive value (NPV) to distinguish prepubertal 
and pubertal girls.
Ultrasound evaluation allows for refined 
characterization of early thelarche
Minor disagreements between Tanner and US breast sta-
ging were encountered on the intra-individual level, and 
we next decided to investigate the possible endocrine im-
plications of these discrepancies. Stratifying each of the 
established Tanner B stages by the corresponding breast 
stages obtained by US, we observed no biochemical differ-
ences between US B strata in pubertal girls (Tanner B2-5). 
However, statistically significant endocrine discrepancies 
were evident upon stratification of clinically prepubertal 
Tanner B1 girls by US B stages (Table 3). Among these 264 
prepubertal girls, individually evaluated as Tanner B1, US 
breast morphology was radiologically discernable by US 
as mainly prepubertal US B0 (139/264 = 52.7%) or US 
B1 (111/264 = 42.0%), but pubertal attainment of glan-
dular tissue was also evident in a subset of US B2 girls 
(14/264 = 5.3%). Notably, both age and serum levels of 
E1 were significantly higher in US B1 relative to US B0 
(P < 0.05 and P < 0.01, respectively, Mann-Whitney U). 
Comparing the US B1 and US B2 strata by Mann-Whitney 
U tests, we observed statistically significant differences in 
Figure 2. Hormone references in relation to chronological age. Age references for (a) estradiol (E2; No. = 547), (b) estrone (E1; No. = 561), (c) lutein-
izing hormone (LH; No. = 600), (d) follicle-stimulating hormone (FSH; No. = 599), (e) sex hormone–binding globulin (SHBG; No. = 601) and (f) LH/FSH 
ratio (No. = 599). All healthy participants were included, and the variable number of observations for the individual hormones were due to insufficient 
serum volume to determine the respective analytes. Filled dots represent prepubertal girls (Tanner B1) and open dots represent pubertal girls (Tanner 
B2+). Continuous median, lower limit (2.5th percentile) and upper limit (97.5th percentile) centiles with 90% CIs were estimated by nonparametric 
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Table 1. Reference Intervals for Tanner and US Breast Stages
95% Reference intervals
Reference Stage No.   Median 2.5th percentile (90% CI) 97.5th percentile (90% CI) Z
Estradiol (E2), pmol/L LC-MS/MS
Tanner stage B1 260 4.8 0.9 (0.7-1.1) 38.0 (22.9-65.2) -
B2 69 24.0 6.0 (4.9-6.9) 204.4 (120-291) a
B3 63 90.0 4.3 (0.7-10.6) 280.6 (221-302) a
B4 73 177 26.3 (7.2-56.5) 803.4 (634-1020) a
B5 76 150 48.4 (42.0-65.0) 981.5 (838-1175) n.s.
Ultrasound stage US B0 134 4.4 0.8 (0.7-1.1) 38.8 (20.3-61.4) -
US B1 111 5.1 1.2 (0.7-1.7) 42.6 (20.0-71.0) n.s.
US B2 78 23.5 3.7 (2.3-6.0) 203.3 (148-302) a
US B3 60 108 6.0 (3.3-10.4) 453.3 (303-536) a
US B4 90 151 19.9 (0.7-58.3) 834.3 (662-1020) a
US B5 63 160 30.2 (7.2-55.8) 1012.7 (779-1175) n.s.
Estrone (E1), pmol/L LC-MS/MS
Tanner stage B1 260 14.0 4.4 (3.6-5.0) 37.9 (34.0-45.0) -
B2 69 34.0 12.6 (12.0-14.5) 119.1 (96.3-139) a
B3 66 78.5 12.3 (0.4-31.0) 192.4 (151-214) a
B4 78 118 41.8 (27.0-53.0) 398.9 (290-423) a
B5 81 135 55.2 (50.0-63.0) 476.1 (385-573) a
Ultrasound stage US B0 134 13.0 3.9 (2.7-4.5) 38.8 (33.8-47.8) -
US B1 111 16.0 5.6 (3.1-6.3) 41.9 (34.0-75.0) a
US B2 78 32.5 11.2 (7.3-13.8) 154.5 (100-214) a
US B3 62 80.5 17.1 (14.9-26.3) 192.0 (177-199) a
US B4 97 115 33.4 (0.4-53) 426.9 (337-573) a
US B5 67 135 43.4 (27.0-57.8) 435.9 (387-463) a
LH, IU/L IMMULITE 2000 XPi
Tanner stage B1 269 0.1 ≤ 0.1 0.5 (0.4-0.6) -
B2 73 0.3 ≤ 0.1 3.9 (2.3-5.4) a
B3 71 2.7 ≤ 0.1 8.6 (6.8-9.5) a
B4 90 3.6 0.2 (0.1-0.6) 39.6 (16.5-54.2) a
B5 89 4.6 0.7 (0.4-1.0) 34.8 (17.3-47.1) n.s.
Ultrasound stage US B0 140 0.1 ≤ 0.1 0.4 (0.3-0.5) -
US B1 114 0.1 ≤ 0.1 0.4 (0.4-1.0) n.s.
US B2 83 0.2 ≤ 0.1 3.6 (2.2-5.4) a
US B3 65 2.8 0.1 (0.1-0.2) 12.2 (8.7-16.9) a
US B4 111 4.3 0.2 (0.1-0.5) 37.6 (15.2-54.2) a
US B5 74 4.1 0.4 (0.1-0.9) 34.7 (18.3-47.1) n.s.
FSH, IU/L IMMULITE 2000 XPi
Tanner stage B1 267 1.6 0.4 (0.4-0.5) 5.3 (4.6-6.4) -
B2 73 3.3 1.3 (1.2-1.3) 9.1 (7.4-12.1) a
B3 71 5.4 1.3 (1.1-1.6) 10.6 (8.4-12.3) a
B4 90 5.5 0.4 (0.1-1.2) 11.1 (9.5-13.3) n.s.
B5 90 6.1 1.4 (1.1-1.9) 10.9 (10.0-11.5) n.s.
Ultrasound stage US B0 138 1.6 0.4 (0.3-0.5) 5.1 (3.5-7.2) -
US B1 114 1.5 0.4 (0.1-0.6) 5.0 (4.5-5.6) n.s.
US B2 83 3.2 1.2 (1.1-1.3) 7.8 (7.3-8.1) a
US B3 65 5.6 0.7 (0.1-1.5) 10.6 (8.5-12.3) a
US B4 112 5.6 1.2 (0.1-2.1) 11.4 (8.7-13.3) n.s.
US B5 74 6.1 1.0 (0.3-1.7) 11.0 (10.1-11.5) n.s.
SHBG, nmol/L IMMULITE 2000 XPi
Tanner stage B1 269 102 51.5 (46.0-56.8) 177.7 (≥ 174) -
B2 73 78.0 35.6 (30.0-41.6) 164.2 (≥ 137) a
B3 71 62.0 28.1 (26.0-32.8) 126.3 (114-130) a
B4 90 60.5 27.9 (24.0-32.6) 110.9 (101-121) a
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serum levels of E2 (P < 0.05), FSH (P < 0.01) and SHBG 
(P < 0.05), corresponding to a highly distinct endocrine 
phenotype indicated by the endocrine profile (P < 0.001). 
Importantly, these endocrine differences were observed 
despite no significant age difference between the US B1 and 
US B2 subgroups. In this comparison, the endocrine profile 
emerged as the most statistically significant variable.
Discussion
In the current study, 601 healthy Norwegian girls were evalu-
ated by both clinical and US breast evaluations, allowing 
for exceptional endocrine and methodological comparisons. 
Overall, the girls in the current Norwegian cohort exhibited 
median age at occurrence of Tanner B2 at 10.4 years, US 
B2 at 10.2 years, and menarche at 12.7 years (7), which is 
comparable to other Western countries (35-38). The cohort 
was representative of the general Norwegian demography, 
having a ~90% majority Caucasian population. Agreement 
between the 2 breast staging methods was satisfactory, as 
previously described (7, 21). Interestingly, our participants 
perceived US as a less invasive procedure compared to pal-
pation, and the majority (67.3%) of the girls favored the US 
evaluation (our unpublished observations).
Although reference intervals for US and Tanner breast 
stage were biochemically comparable overall, US enabled 
Table 2. Predictive Markers of Female Puberty Onset
Girls age 8-12 y Tanner B1 Tanner B2+ Receiver-operating characteristics (ROC) curve output
AUC PPV (%) NPV (%) Cutoff Sens. Spec.
Tanner B Sample size, No. 185 116       
Age, y 9.3 (8.0-11.8) 10.5 (8.6-11.9) 0.85 71.4 85.1 10.2 y 0.78 0.81
Endocrine profile, AU −1.0 (–1.6 to 0.5) 0.1 (−1.1 to 2.6) 0.91 75.0 88.4 -0.5 AU 0.80 0.85
Estradiol E2, pmol/L 6.2 (1.0-40.7) 24.0 (6.4-126) 0.90 84.8 84.1 19.5 pmol/L 0.72 0.92
Estrone E1, pmol/L 17.0 (5.1-39.1) 33.0 (13.5-98) 0.84 77.8 86.0 28.5 pmol/L 0.77 0.87
LH, IU/L 0.1 (≤ 0.5) 0.2 (0.1-2.4) 0.84 82.8 81.2 0.2 IU/L 0.66 0.91
FSH, IU/L 1.7 (0.6-5.1) 3.3 (1.3-7.5) 0.82 67.9 84.0 2.6 IU/L 0.76 0.77
SHBG, nmol/L 102 (52-179) 75 (37-159) 0.80 66.9 82.2 86.5 nmol/L 0.73 0.77
 Girls age 8–12 y US B0/1 US B2+ AUC PPV (%) NPV (%) Cutoff Sens. Spec.
Ultrasound Sample size, No. 170 126       
Age, y 9.3 (8.0-11.9) 10.8 (8.5-12.0) 0.81 68.2 83.1 9.9 y 0.81 0.72
Endocrine profile, AU −1.0 (−1.6 to 0.45) 0.4 (−1.1 to 4.8) 0.90 71.9 88.8 -0.7 AU 0.85 0.78
Estradiol E2, pmol/L 6.3 (1.0-41.6) 35.0 (3.3-242) 0.87 86.8 79.1 19.5 pmol/L 0.66 0.92
Estrone E1, pmol/L 17.0 (4.7-39.9) 43.0 (12.0-139) 0.84 79.4 80.6 28.5 pmol/L 0.71 0.87
LH, IU/L 0.1 (≤ 0.4) 0.4 (0.1-6.7) 0.81 86.8 77.1 0.3 IU/L 0.63 0.93
FSH, IU/L 1.7 (0.5-5.0) 3.8 (1.3-8.1) 0.82 70.8 79.4 2.6 IU/L 0.73 0.78
SHBG, nmol/L 102 (54-180) 70 (30-133) 0.79 71.7 77.3 84.5 nmol/L 0.68 0.80
Baseline characteristics (median, 95% CI) for girls grouped by Tanner or US definitions of puberty onset in the thelarche age window 8 to 12 years were lever-
aged in receiver-operating characteristics (ROC) analyses. Sens. (sensitivity) and Spec. (specificity) represent ROC curve coordinates for the optimal cutoff point.
Abbreviations: AU, arbitrary units; AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value. 
95% Reference intervals
Reference Stage No.   Median 2.5th percentile (90% CI) 97.5th percentile (90% CI) Z
Ultrasound stage US B0 140 103 56.0 (51.0-64.0) 179.4 (≥ 176) -
US B1 114 99.5 50.4 (37.0-57.9) 169.2 (≥ 155) a
US B2 83 83.0 28.5 (14.0-39.2) 158.6 (≥ 130) a
US B3 65 62.0 27.0 (25.0-33.2) 130.4 (102-158) a
US B4 112 57.0 19.3 (12.0-26.5) 119.0 (104-126) a
US B5 74 56.5 19.8 (17.0-26.0) 102 (92.5-112) n.s.
Sample size (n) and analyte levels corresponding to the median and resampled 95% reference intervals are presented for indicated puberty breast stage partitions. 
Column “Z” summarizes Harris-Boyd standard deviate tests to determine justified partitioning of current and the previous partition (ayes) or not (n.s., not 
significant). 
Abbreviations: B, Tanner breast stage; E1, estrone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone–binding glob-
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detection of glandular tissue in a subset of clinically pre-
pubertal girls with distinct biochemical baseline charac-
teristics. From the stratification of clinically prepubertal 
(Tanner B1) girls by US B stages in Table 2, we observed sig-
nificant endocrine profile differences between the substrata 
of prepubertal (US B1) and pubertal (US B2) girls. Although 
the subgroup of girls with detectable glandular tissue by 
US (US B2) was small, this finding implies that endocrine 
profiling by PCA may provide more sensitivity than any 
singular hormone in context of detecting thelarche. Further 
studies are warranted to explore the use-case for tailored 
endocrine profiles as predictive or diagnostic markers of 
endocrinopathies, including hypogonadism and disorders 
of sexual development.
The application of endocrine profiling in the current 
study has limitations and warrants discussion. PCA was 
applied to capture the total variance of 5 hormone con-
centrations from 403 premenarcheal girls. The first prin-
cipal component, PC1, explained 70% of the total dataset 
variance and thus the PC1 scores associated with each 
study participant were leveraged as a composite endocrine 
profile index. The rationale for this endocrine profile was 
that its constituent hormones are integral components of 
the pubertal hypothalamic-pituitary-gonadal signaling 
axis and subject to reciprocal regulation. Loading other 
pertinent hormone dimensions into the endocrine profile 
would arguably generate additional complexity and depth. 
The application of endocrine profiling by PCA cluster ana-
lysis was recently applied to extract distinct endocrine 
phenotype clusters in a longitudinal study of female pu-
berty (18). In contrast, our approach was to generate a ref-
erence endocrine profile for normal puberty development. 
As shown in Table 2, the composite endocrine profile index 
was an excellent marker of thelarche, but in terms of ROC 
diagnostic performance it was only marginally better than, 
or practically equivalent to that of E
2 levels alone. However, 
the occurrence of US thelarche morphology in clinically 
prepubertal girls in Table 3 was marked with a higher de-
gree of statistical confidence by the endocrine profile than 
by E2 alone. These findings imply that endocrinological in-
vestigations of altered puberty timing in some cases may 
benefit from PCA profiling. Automated computation for 
endocrine profiling may provide added value to existing 
laboratory systems or clinical decision trees. In a previous 
study, Fugl et  al observed that baseline level of LH was 
the better analyte variable to determine thelarche (39). 
Notably, this study included a sample size of only 43 girls, 
with a late minimum inclusion age of 9.8 years.
A central undertaking in the current work was the con-
struction of reference intervals compatible with previously 
defined US breast stages (7, 20, 21). Table 1 was config-
ured to juxtapose reference intervals for clinical Tanner B 
stages and US B stages. Notably, applying the Harris-Boyd 
standard deviate test criteria, there were no cases where hor-
mone levels differed significantly between corresponding 
Tanner B and US B stages throughout puberty or when 
pooled observations in US B0/1 was compared to Tanner 
B1. This implies that these 2 ordinal methods of breast sta-
ging are principally compatible in endocrinological terms, 
with matching breast stages aligning biochemically despite 
different methodological rationales. However, US enabled 
stratification of girls nearing thelarche.
Our reference intervals should be interpreted with some 
precautions. The current references represent average hor-
mone levels throughout the morning and early noon, and 
do not account for intra-day variation for gonadotropins 
and estrogen levels. In this regard, the diurnal rhythm for 
estrogen, LH and FSH secretion have been extensively 
Table 3. Baseline Characteristics for Clinically Prepubertal Girls Stratified by Ultrasound Breast Stages
Clinical Tanner B1 (prepubertal)
Variable US B0 US B1 US B2
Stratum size, No. 139 111 14
Age, years 8.2 (6.5–11.4) 8.9* (6.8–11.9) 9.7 (8.0–11.6)
Pubic hair (PH2+), % 6.6% 5.4% 40.0%
Endocrine profile, AU −1.1 (−1.7 to 0.1) −1.1 (−1.5 to 0.0) −0.6*** (−1.2 to 1.8)
Estradiol E2, pmol/L 4.4 (0.8-30.6) 4.90 (1.4-21.3) 12.5* (2.3-112.0)
Estrone E1, pmol/L 13.0 (4.2-35.7) 16.0** (5.4-34.0) 20.5 (7.3-60.0)
LH, IU/L 0.1 (0.1-0.4) 0.1 (0.1-0.4) 0.1 (0.1-2.1)
FSH, IU/L 1.6 (0.4-4.5) 1.5 (0.5-4.9) 2.4** (1.1-7.9)
SHBG, nmol/L 103 (56-180) 101 (53-169) 87* (14-128)
Baseline characteristics (median, 95% CI) for 264 girls with a prepubertal clinical presentation, stratified by US breast stages. Statistically significant differences 
(Mann-Whitney U) between pairwise strata (US B0 vs US B1, or US B1 vs US B2) are annotated. 
Abbreviations: AU, arbitrary units; E1, estrone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone–binding globulin. 
Significant differences obtained by Mann-Whitney U tests between columns US B0 and US B1, or between US B1 and US B2 were denoted *P < 0.05, **P < 0.01 
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studies by others (40-42). Due to logistical constraints, 
we were unable to obtain fasting morning samples and, 
in line with similar studies (25, 43-46) our references rely 
on sample power to squelch diurnal secretion patterns and 
may thus be representative for outpatient clinics. Further, 
we did not account for latent hormone fluctuations asso-
ciated with monthly cyclicity in premenarcheal girls, and 
postmenarche data were not stratified by menstruation 
cycle phase at the time of blood draw.
In conclusion, we have provided the first set of statistic-
ally robust hormone references for US breast staging, in com-
parison with traditional Tanner B stages for female puberty. 
Our results demonstrate a high degree of agreement between 
the 2 methods of puberty staging, both in terms of age at 
stage occurrences and endocrine parameters. However, US 
enabled detection of nonpalpable glandular tissue in a subset 
of clinically prepubertal girls, and this phenotype was cor-
roborated by a pubertal endocrine profile. Furthermore, we 
have demonstrated that index scores from endocrine pro-
filing by PCA represents a useful predictive marker of pu-
berty onset with a possible use-case in detecting pediatric 
endocrinopathies associated with altered puberty onset.
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